Skip to main content

ORIGINAL RESEARCH article

Front. Allergy
Sec. Rhinology
Volume 5 - 2024 | doi: 10.3389/falgy.2024.1531788
This article is part of the Research Topic Recent Advances in Rhinology 2024 View all 4 articles

EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR

Provisionally accepted
Glenis Kathleen Scadding Glenis Kathleen Scadding 1*Diego Marcelo Conti Diego Marcelo Conti 2Sophie Scheire Sophie Scheire 3Vibeke Backer Vibeke Backer 4M Blaiss M Blaiss 5Lars Olaf Cardell Lars Olaf Cardell 6De Yun Wang De Yun Wang 7A Ellis A Ellis 8W Fokkens W Fokkens 9Adam T Fox Adam T Fox 10T Gilbert Kruz T Gilbert Kruz 11S Halken S Halken 12Peter Hellings Peter Hellings 13V Hox V Hox 14Livije Kalogjera Livije Kalogjera 15M Kostrabova M Kostrabova 16Susanne Lau Susanne Lau 17S Marinho S Marinho 18Marinda McDonald Marinda McDonald 19Ralph Mösges Ralph Mösges 20JOAQUIM MULLOL JOAQUIM MULLOL 21S Nasser S Nasser 22RUBY PAWANKAR RUBY PAWANKAR 23David Price David Price 24D Ryan D Ryan 25G Scadding G Scadding 26P Smith P Smith 27Marta Vazquez-Ortiz Marta Vazquez-Ortiz 28U Wahn U Wahn 29Luo Zhang Luo Zhang 30Philippe Gevaert Philippe Gevaert 3
  • 1 Royal National ENT Hospital and University College, London., London, United Kingdom
  • 2 Allergy and Clinical Immunology Research Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium
  • 3 Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Belgium., Ghent, Belgium
  • 4 Department of Otorhinolaryngology, Head & Neck Surgery, and Audiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark., Copenhagen, Denmark
  • 5 Medical College of Georgia at Augusta University, Augusta Georgia USA., Georgia, United States
  • 6 Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden
  • 7 Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore., Singapore, Singapore
  • 8 Division of Allergy & immunology, Department of Medicine, Queen's University, Kingston, ON Canada., Ontario, Canada
  • 9 Department of Otorhinolaryngology, Amsterdam University Medical Centres, Amsterdam, The Netherlands., Amsterdam, Netherlands
  • 10 Guy’s & St Thomas’ Hospitals NHS Foundation Trust, London, UK., London, United Kingdom
  • 11 Patient Advisory Board of the European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium., Brussels, Belgium
  • 12 Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark., Odense, Denmark
  • 13 Clinical Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium., Leuven, Belgium
  • 14 Department of Otorhinolaryngology, Cliniques Universitaires Saint Luc, Brussels, Belgium., Brussels, Belgium
  • 15 Dept of Otorhinolaryngology/Head and Neck Surgery. University Hospital Centre "Sestre milosrdnice". Zagreb School of Medicine. Zagreb, Croatia., Zagreb, Croatia
  • 16 Patient Advisory Board of the European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium., Bruselas, Belgium
  • 17 Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany., Berlin, Germany
  • 18 Allergy Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust and The University of Manchester, Manchester, UK., Manchester, United Kingdom
  • 19 The Allergy Clinic. Blairgowrie. Johannesburg SA., Johannesburg, South Africa
  • 20 ClinCompetence Cologne GmbH, Theodor-Heuss-Ring 14, 50668 Cologne, Germany., Cologne, Germany
  • 21 Rhinology Unit & Smell Clínic, Department of Otorhinolaryngology, Hospital Clínic Barcelona, Universitat de Barcelona; FRCB-IDIBAPS; CIBERES. Barcelona, Catalonia, Spain., Barcelona, Spain
  • 22 Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Cambridge, United Kingdom
  • 23 Department of Pediatrics, Nippon Medical School, Bunkyo-ku, Tokyo, Japan., Tokyo, Japan
  • 24 Observational and Pragmatic Research Institute, Singapore, Singapore., Singapore, Singapore
  • 25 Usher institute, University of Edinburgh, Edinburgh, Scotland., Edinburgh, United Kingdom
  • 26 Allergy department, Royal Brompton Hospital, London, UK., London, United Kingdom
  • 27 Griffth University, Southport, Queensland, Australia., Queensland, Australia
  • 28 Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, United Kingdom., London, United Kingdom
  • 29 Charite University Medicine, Berlin., Berlin, Germany
  • 30 Department of Otolaryngology Head and Neck surgery and department of Allergy. Beijing TongRen Hospital, Capital Medical University. Beijing, China., Beijing, China

The final, formatted version of the article will be published soon.

    Allergic rhinitis (AR), the most prevalent immunological disease, affects approximately 400 million individuals globally and can significantly impact quality of life (QoL). Despite nearly 25 years of guidelines, AR remains largely under-diagnosed, suboptimally treated and poorly controlled. In the light of new knowledge and treatment options, there is a necessity to update or revise fundamental AR definitions to facilitate communication across diverse specialties engaged in its treatment and to improve patient care. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) convened a meeting of experts and patient representatives to deliberate the optimal methodology for measuring AR treatment responses and establishing novel treatment goals. This paper presents a consensus on revised AR definitions, including control, severe allergic rhinoconjunctivitis (SARC), refractory severe allergic rhinoconjunctivitis (R-SARC), remission, resolution, improvement, exacerbation, treatable traits (TTs), treat to target, relapse, progression, disease modification, and prevention.

    Keywords: allergic rhinitis, Quality of Life, definitions, severe allergic rhinoconjunctivitis (SARC), refractory severe refractory allergic rhinoconjunctivitis (R-SARC), biologics, allergen immunotherapy (AIT), Control

    Received: 20 Nov 2024; Accepted: 30 Dec 2024.

    Copyright: © 2024 Scadding, Conti, Scheire, Backer, Blaiss, Cardell, Wang, Ellis, Fokkens, Fox, Gilbert Kruz, Halken, Hellings, Hox, Kalogjera, Kostrabova, Lau, Marinho, McDonald, Mösges, MULLOL, Nasser, PAWANKAR, Price, Ryan, Scadding, Smith, Vazquez-Ortiz, Wahn, Zhang and Gevaert. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Glenis Kathleen Scadding, Royal National ENT Hospital and University College, London., London, United Kingdom

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.